LRP4突变促进复发性肝细胞癌肿瘤进展并介导抗PD-1治疗耐药
研究对63对原发与复发肝细胞癌行全外显子测序并联合既往43对全基因组测序,另对203例复发患者行Sanger测序验证。复发肿瘤LRP4突变率7.8%(24/309)高于原发肿瘤0.97%(3/309)(p<0.001),LRP4突变者二次肝切除后预后更差,机制上通过激活β-catenin信号抑制CCL4表达分泌、减少瘤内cDC1与CD8+T细胞浸润,导致抗PD-1治疗耐药。
要点
- 复发肝细胞癌LRP4突变率7.8%(24/309),原发肿瘤仅0.97%(3/309)(p<0.001)。
- 携带LRP4突变的复发患者二次肝切除后预后更差,且未从二次术后抗PD-1治疗中获益。
- β-catenin抑制剂在人源荷瘤小鼠中逆转LRP4诱导的抗PD-1耐药。
核心结论
- 研究识别出在复发性肝细胞癌中具有重要作用的LRP4突变。
- 失活型LRP4突变与抗PD-1治疗耐药相关,可能作为复发性肝细胞癌精准治疗的生物标志物。
研究设计与样本
- 对63对匹配的原发与复发肝细胞癌肿瘤行全外显子测序,并联合既往研究中43对样本的全基因组测序结果。
- 采用Sanger测序在另外203例复发性肝细胞癌患者中鉴定LRP4全部编码外显子。
- 开展生物功能学实验及人源荷瘤小鼠实验探讨LRP4突变的作用机制。
主要发现
- 复发肿瘤中LRP4体细胞突变率为7.8%(24/309),原发肿瘤为0.97%(3/309)(p<0.001)。
- 携带LRP4突变的患者第二次肝切除术后预后更差。
- 失活型LRP4突变促进肿瘤进展和免疫抑制。
- 突变型LRP4通过激活β-catenin信号抑制C-C趋化因子配体4(CCL4)的表达和分泌,减少瘤内经典1型树突状细胞和CD8+T细胞浸润,导致抗程序性细胞死亡蛋白-1治疗耐药。
- 携带LRP4突变的复发性肝细胞癌患者在第二次切除术后未从抗程序性细胞死亡蛋白-1治疗中获益。
关键数值与推荐
- 复发性肝细胞癌LRP4突变率7.8%(24/309),原发肿瘤0.97%(3/309),p<0.001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: HCC recurrence is a major factor limiting long-term survival and the cause of most deaths in patients with HCC. However, molecular characterization and potential therapeutic targets of recurrent HCC remain mostly unknown. APPROACH AND RESULTS: We performed whole-exome sequencing in 63 matched primary and recurrent HCC tumors and combined the data with whole-genome sequencing results in 43 paired samples from our previous study. Sanger sequencing was used to identify all low-density lipoprotein receptor-related protein 4 ( LRP4 ) coding exons in 203 additional patients with recurrent HCC. We identified LRP4 somatic mutations in 7.8% (24/309) of recurrent tumors and only 0.97% (3/309) of primary tumors ( p <0.001). Prognosis after the second liver resection was poorer in patients with an LRP4 mutation. Biofunctional investigations demonstrated that inactivating LRP4 mutations promoted tumor progression and immunosuppression. Mechanistically, mutated LRP4 reduced intratumoral conventional type 1 dendritic cell and CD8 + T cell infiltration by repressing C-C motif chemokine ligand 4 expression and secretion through activation of β-catenin signaling, resulting in resistance to anti-programmed cell death protein-1 therapy. Patients with recurrent HCC carrying an LRP4 mutation did not benefit from anti-programmed cell death protein-1 treatment after their second resection surgery. A β-catenin inhibitor-reversed LRP4-induced resistance to anti-programmed cell death protein-1 therapy in humanized tumor-bearing mice. CONCLUSIONS: Our results identified novel LRP4 mutations important in recurrent HCC. Inactivating LRP4 mutations were associated with resistance to anti-programmed cell death protein-1 therapy and could be useful biomarkers for precision therapy in patients with recurrent HCC.
引用
- Sun R, Liu K, Pan S, et al. LRP4 mutations promote tumor progression and resistance to anti-PD-1 therapy in recurrent hepatocellular carcinoma. Hepatology. 2024. PMID: 39723987. doi:10.1097/HEP.0000000000001212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。